| Polymorphic hydroxylation of debrisoquine in man A Mahgoub, LG Dring, JR Idle, R Lancaster, RL Smith The Lancet 310 (8038), 584-586, 1977 | 1527 | 1977 |
| A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. DA Evans, A Mahgoub, TP Sloan, JR Idle, RL Smith Journal of Medical Genetics 17 (2), 102-105, 1980 | 657 | 1980 |
| Nomenclature for human CYP2D6 alleles AK Daly, J Brockmoller, F Broly, M Eichelbaum, WE Evans, FJ Gonzalez, ... Pharmacogenetics and Genomics 6 (3), 193-201, 1996 | 608 | 1996 |
| Metabolic oxidation phenotypes as markers for susceptibility to lung cancer R Ayesh, JR Idle, JC Ritchie, MJ Crothers, MR Hetzel Nature 312 (5990), 169-170, 1984 | 557 | 1984 |
| Metabolism of melatonin by human cytochromes p450 X Ma, JR Idle, KW Krausz, FJ Gonzalez Drug metabolism and disposition 33 (4), 489-494, 2005 | 401 | 2005 |
| A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A gnes and identification of variant CYP2A6 alleles P Fernandez-Salguero, SMG Hoffman, S Cholerton, H Mohrenweiser, ... American Journal of Human Genetics 57 (3), 651, 1995 | 381 | 1995 |
| The role of individual human cytochrpmes P450 in drug metabolism and clinical response S Cholerton, AK Daly, JR Idle Trends in pharmacological sciences 13, 434-439, 1992 | 372 | 1992 |
| Metabolomics JR Idle, FJ Gonzalez Cell metabolism 6 (5), 348-351, 2007 | 361 | 2007 |
| Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy H Furuya, P Fernandez-Salguero, W Gregory, H Taber, A Steward, ... Pharmacogenetics and Genomics 5 (6), 389-392, 1995 | 354 | 1995 |
| LC-MS-based metabolomics in drug metabolism C Chen, FJ Gonzalez, JR Idle Drug metabolism reviews 39 (2-3), 581-597, 2007 | 324 | 2007 |
| Mutant debrisoquine hydroxylation genes in Parkinson's disease M Armstrong, AK Daly, S Cholerton, JR Idle, DN Bateman The Lancet 339 (8800), 1017-1018, 1992 | 319 | 1992 |
| Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology VM Steen, OA Andreassen, AK Daly, T Tefre, AL Borresen, JR Idle, ... Pharmacogenetics and Genomics 5 (4), 215-223, 1995 | 306 | 1995 |
| Xenobiotic metabolomics: major impact on the metabolome CH Johnson, AD Patterson, JR Idle, FJ Gonzalez Annual review of pharmacology and toxicology 52 (1), 37-56, 2012 | 305 | 2012 |
| Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling AD Patterson, O Maurhofer, D Beyoğlu, C Lanz, KW Krausz, T Pabst, ... Cancer research 71 (21), 6590-6600, 2011 | 304 | 2011 |
| The incidence and severity of nifedipine‐induced gingival overgrowth S Barclay, JM Thomason, JR Idle, RA Seymour Journal of clinical periodontology 19 (5), 311-314, 1992 | 301 | 1992 |
| Metabolic polymorphisms AK Daly, S Cholerton, W Gregory, JR Idle Pharmacology & therapeutics 57 (2-3), 129-160, 1993 | 289 | 1993 |
| Pharmacogenetic phenotyping and genotyping: present status and future potential FJ Gonzalez, JR Idle Clinical pharmacokinetics 26 (1), 59-70, 1994 | 273 | 1994 |
| Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. RR Shah, NS Oates, JR Idle, RL Smith, JD Lockhart Br Med J (Clin Res Ed) 284 (6312), 295-299, 1982 | 263 | 1982 |
| Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene R Løvlie, AK Daly, A Molven, JR Idle, VM Steen FEBS letters 392 (1), 30-34, 1996 | 255 | 1996 |
| The metabolomic window into hepatobiliary disease D Beyoğlu, JR Idle Journal of hepatology 59 (4), 842-858, 2013 | 249 | 2013 |
Frank J. GonzalezNational Cancer InstituteПідтверджена електронна адреса в mail.nih.gov